We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

26 hedge funds and large institutions have $624K invested in Aspire Biopharma Warrant in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $604K → $624K (+$20.2K)

13% less funds holding

Funds holding: 30 → 26 (-4)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
26
Holders Change
-4
Holders Change %
-13.33%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
4
Closed
4
Calls
$13K
Puts
–
Net Calls
+$13K
Net Calls Change
-$785K

Top Buyers

Rank Fund Capital Flow
1
LP
LMR Partners
United Kingdom
+$3.38K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$1.97K
2
MC
Meteora Capital
Florida
-$888
3
Walleye Trading
Walleye Trading
New York
-$354
4
WA
Whitebox Advisors
Minnesota
-$169
5
PC
Periscope Capital
Ontario, Canada
-$57
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$246K – – –
HCM
2
Highbridge Capital Management
New York
$80.8K – – –
SCM
3
Saba Capital Management
New York
$40.6K – – –
LA
4
Linden Advisors
New York
$36.2K – – –
AA
5
AQR Arbitrage
Connecticut
$30.8K – – –
PC
6
Periscope Capital
Ontario, Canada
$26.3K -$57 -2,100 -0.4%
SC
7
Sculptor Capital
New York
$20.6K – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$20.6K – – –
WAM
9
Wolverine Asset Management
Illinois
$19.1K – – –
Barclays
10
Barclays
United Kingdom
$16.6K – – –
TCA
11
Taconic Capital Advisors
New York
$14.3K – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$9.5K – – –
CCM
13
Context Capital Management
California
$8.31K – – –
Nomura Holdings
14
Nomura Holdings
Japan
$7.2K – – –
PAMP
15
Polar Asset Management Partners
Ontario, Canada
$6.58K – – –
CS
16
Clear Street
New York
$6.58K -$3 -100 -0.1%
LP
17
LMR Partners
United Kingdom
$5.94K +$3.38K +125,000 New
WA
18
Whitebox Advisors
Minnesota
$5.64K -$169 -6,250 -5%
CSD
19
Clear Street Derivatives
New York
$5.04K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$4.75K – – –
CCM
21
CAAS Capital Management
New York
$3.56K – – –
PMAM
22
Picton Mahoney Asset Management
Ontario, Canada
$3K – – –
BOCH
23
Blue Owl Capital Holdings
New York
$2.5K – – –
OAC
24
OMERS Administration Corp
Ontario, Canada
$1.19K – – –
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$1.05K – – –
1
2

ASBPW Hedge Fund Activity: Q4 2024 in Review

26 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q4 2024, worth a combined $624K — up 3.3% from $604K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ASBPW and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was LMR Partners, opening a new position worth an estimated $3.38K. The largest seller was Walleye Capital, exiting entirely with an estimated $1.97K sold.

  • 26 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q4 2024, down from 30 in Q3 2024.
  • Funds reported $624K of Aspire Biopharma Warrant stock for Q4 2024, up 3.3% quarter-over-quarter.
  • 1 fund opened new Aspire Biopharma Warrant positions in Q4 2024 and 4 closed out, a net change of -3 holders.
  • The largest Aspire Biopharma Warrant buyer in Q4 2024 was LMR Partners, an estimated $3.38K added.
  • The largest Aspire Biopharma Warrant seller in Q4 2024 was Walleye Capital, an estimated $1.97K sold.

Based on aggregated 13F filings for Q4 2024.